# Niacin Plus Statin to Prevent Vascular Events

> **NCT00120289** · PHASE3 · TERMINATED · sponsor: **Axio Research. LLC** · enrollment: 3414 (actual)

## Conditions studied

- Cardiovascular Diseases
- Heart Diseases
- Cerebrovascular Accident
- Coronary Disease
- Atherosclerosis
- Myocardial Infarction

## Interventions

- **DRUG:** Extended release niacin
- **DRUG:** Simvastatin

## Key facts

- **NCT ID:** NCT00120289
- **Lead sponsor:** Axio Research. LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-09
- **Primary completion:** 2012-09
- **Final completion:** 2012-12
- **Target enrollment:** 3414 (ACTUAL)
- **Why stopped:** AIM-HIGH was stopped on the recommendation of the DSMB because of lack of efficacy of niacin in preventing primary outcome events.
- **Last updated:** 2016-04-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00120289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00120289, "Niacin Plus Statin to Prevent Vascular Events". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00120289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*